BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
The world's leading humanized monoclonal antibody preparation process and large-scale continuous mammalian cells culture technology.
BPL developed the first humanized monoclonal antibody drug Nimotuzumab (trade name: Taixinsheng) for the treatment of malignant tumors in China.
We sincerely welcome talents from all walks of life to join BPL, qualified as post-doctoral research workstation with diversified professional positions.